Panbela Therapeutics Statistics
Total Valuation
Panbela Therapeutics has a market cap or net worth of 1.78 million. The enterprise value is 5.92 million.
| Market Cap | 1.78M |
| Enterprise Value | 5.92M |
Important Dates
The next estimated earnings date is Monday, November 11, 2024.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Panbela Therapeutics has 4.85 million shares outstanding. The number of shares has increased by 16,008.55% in one year.
| Shares Outstanding | 4.85M |
| Shares Change (YoY) | +16,008.55% |
| Shares Change (QoQ) | +55.31% |
| Owned by Insiders (%) | 0.00% |
| Owned by Institutions (%) | n/a |
| Float | 4.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.16 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.02 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -112.19 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -128.31% |
| Return on Capital (ROIC) | -1,026.06% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -4.71M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -97.45% in the last 52 weeks. The beta is 0.98, so Panbela Therapeutics's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -97.45% |
| 50-Day Moving Average | 0.35 |
| 200-Day Moving Average | 0.71 |
| Relative Strength Index (RSI) | 56.01 |
| Average Volume (20 Days) | 9,526 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.68 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.73M |
| Pretax Income | -28.75M |
| Net Income | -37.71M |
| EBITDA | n/a |
| EBIT | -29.73M |
| Earnings Per Share (EPS) | -18.06 |
Balance Sheet
The company has 59,000 in cash and 4.19 million in debt, giving a net cash position of -4.14 million or -0.85 per share.
| Cash & Cash Equivalents | 59,000 |
| Total Debt | 4.19M |
| Net Cash | -4.14M |
| Net Cash Per Share | -0.85 |
| Equity (Book Value) | -10.57M |
| Book Value Per Share | -2.18 |
| Working Capital | -16.02M |
Cash Flow
| Operating Cash Flow | -20.13M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Panbela Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16,008.55% |
| Shareholder Yield | -16,008.55% |
| Earnings Yield | -4,913.52% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on January 18, 2024. It was a reverse split with a ratio of 0.05.
| Last Split Date | Jan 18, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.05 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |